Our Take
A dispatch from the floor beats a press release; the real story is what biotech still does not know about deploying AI safely in regulated contexts.
Why it matters
Biotech companies are moving AI pilots into production without clear FDA guidance or internal safety frameworks. Practitioners need to hear from peers and regulators on what actually works before committing budget.
Do this week
Regulatory Affairs: Document your current AI use cases and flag which ones lack FDA precedent by end of week, so you can prioritize clarity calls with your legal team.
STAT Reports from BIO 2026 on Biotech's AI Reality Check
STAT News reporter Brittany Trang filed from the BIO 2026 conference in San Diego this week, capturing conversations among biotech executives, FDA officials, and AI startup leaders on how the sector is actually deploying artificial intelligence. The dispatch focuses on the gap between AI enthusiasm and operational certainty in a regulated industry.
The reporting included interviews with Samuel Aronson, president and chief AI officer of AIwithCare; Dianne Paraoan, acting director of the Office of Medical Policy at the FDA's Center for Drug Evaluation and Research; and Tran Le, general manager for life sciences at Hippocratic AI. The framing was direct: does AI actually work in biotech, and who benefits or bears the risk.
The article itself remains behind a STAT+ paywall, but the setup signals a focus on implementation friction rather than vendor claims. Trang's beat covers AI in health and medicine with explicit emphasis on evidence and harm, not marketing narratives.
Biotech Remains Uncertain on AI Safety in Regulated Contexts
Biotech companies operate under FDA oversight. AI deployments in drug discovery, clinical trial design, or patient care generate regulatory questions that neither the industry nor the agency has fully answered. A summer conference dispatch—not a vendor announcement—is where those questions surface.
The presence of an FDA official in the reporting suggests the regulator is listening to real deployment scenarios, not issuing blanket guidance. That asymmetry matters: companies are moving faster than policy, and the BIO conference is where they negotiate what is acceptable.
For in-house teams evaluating AI tools for core workflows (trial matching, safety signal detection, preclinical prediction), the absence of regulatory precedent raises stakes. A tool that works in a pilot does not equal a tool that survives an FDA inspection.
Ask Your Legal and Regulatory Teams What AI Use Cases Need FDA Input
If you oversee AI adoption at a biotech or pharma company, map which use cases touch patient data, clinical outcomes, or regulatory submissions. Cross-reference that map against what the FDA has actually cleared or commented on publicly. Where there is no precedent, escalate to your regulatory affairs team and ask for a position statement before scaling the deployment.
Do not wait for guidance. Document your current controls, your audit trail, and your human oversight layer. When the FDA eventually clarifies expectations, you will need to show you were already compliant.